These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 30504510)

  • 21. Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis.
    Michaud K; Strand V; Shadick NA; Degtiar I; Ford K; Michalopoulos SN; Hornberger J
    Rheumatology (Oxford); 2015 Sep; 54(9):1640-9. PubMed ID: 25877911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IgA anti-citrullinated protein antibodies are associated with flares during DMARD tapering in rheumatoid arthritis.
    Sokolova MV; Hagen M; Bang H; Schett G; Rech J; Steffen U;
    Rheumatology (Oxford); 2022 May; 61(5):2124-2131. PubMed ID: 34508547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multibiomarker disease activity score for rheumatoid arthritis predicts radiographic joint damage in the BeSt study.
    Markusse IM; Dirven L; van den Broek M; Bijkerk C; Han KH; Ronday HK; Bolce R; Sasso EH; Kerstens PJ; Lems WF; Huizinga TW; Allaart CF
    J Rheumatol; 2014 Nov; 41(11):2114-9. PubMed ID: 25128518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
    van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort.
    Shu J; Bykerk VP; Boire G; Haraoui B; Hitchon C; Thorne JC; Tin D; Keystone EC; Pope JE;
    J Rheumatol; 2015 Nov; 42(11):2023-8. PubMed ID: 26329342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada.
    Weijers L; Baerwald C; Mennini FS; Rodríguez-Heredia JM; Bergman MJ; Choquette D; Herrmann KH; Attinà G; Nappi C; Merino SJ; Patel C; Mtibaa M; Foo J
    Rheumatol Int; 2017 Jul; 37(7):1111-1123. PubMed ID: 28560470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms.
    Ajeganova S; van Steenbergen HW; van Nies JA; Burgers LE; Huizinga TW; van der Helm-van Mil AH
    Ann Rheum Dis; 2016 May; 75(5):867-73. PubMed ID: 25972519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis.
    Verstappen M; Niemantsverdriet E; Matthijssen XME; le Cessie S; van der Helm-van Mil AHM
    Arthritis Res Ther; 2020 Nov; 22(1):276. PubMed ID: 33228814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity.
    Curtis JR; van der Helm-van Mil AH; Knevel R; Huizinga TW; Haney DJ; Shen Y; Ramanujan S; Cavet G; Centola M; Hesterberg LK; Chernoff D; Ford K; Shadick NA; Hamburger M; Fleischmann R; Keystone E; Weinblatt ME
    Arthritis Care Res (Hoboken); 2012 Dec; 64(12):1794-803. PubMed ID: 22736476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis.
    Ma MHY; Defranoux N; Li W; Sasso EH; Ibrahim F; Scott DL; Cope AP
    Arthritis Res Ther; 2020 Jun; 22(1):158. PubMed ID: 32580789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Should we redefine treatment targets in rheumatoid arthritis? Low disease activity is sufficiently strict for patients who are anticitrullinated protein antibody-negative.
    de Punder YM; Hendrikx J; den Broeder AA; Valls Pascual E; van Riel PL; Fransen J
    J Rheumatol; 2013 Aug; 40(8):1268-74. PubMed ID: 23729803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Uptake and Clinical Utility of Multibiomarker Disease Activity Testing in the United States.
    Curtis JR; Xie F; Yang S; Danila MI; Owensby JK; Chen L
    J Rheumatol; 2019 Mar; 46(3):237-244. PubMed ID: 30442830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia.
    Lee YC; Hackett J; Frits M; Iannaccone CK; Shadick NA; Weinblatt ME; Segurado OG; Sasso EH
    Rheumatology (Oxford); 2016 Apr; 55(4):640-8. PubMed ID: 26608972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability.
    Verstappen M; van Mulligen E; de Jong PHP; van der Helm-Van Mil AHM
    RMD Open; 2020 May; 6(1):. PubMed ID: 32393523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can we discontinue synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis?
    Scott IC; Kingsley GH; Scott DL
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S4-8. PubMed ID: 24129128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autoantibodies to posttranslationally modified type II collagen as potential biomarkers for rheumatoid arthritis.
    Strollo R; Ponchel F; Malmström V; Rizzo P; Bombardieri M; Wenham CY; Landy R; Perret D; Watt F; Corrigall VM; Winyard PG; Pozzilli P; Conaghan PG; Panayi GS; Klareskog L; Emery P; Nissim A
    Arthritis Rheum; 2013 Jul; 65(7):1702-12. PubMed ID: 23575908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial.
    Kuijper TM; Luime JJ; de Jong PH; Gerards AH; van Zeben D; Tchetverikov I; de Sonnaville PB; van Krugten MV; Grillet BA; Hazes JM; Weel AE
    Ann Rheum Dis; 2016 Dec; 75(12):2119-2123. PubMed ID: 27283332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis.
    Li W; Sasso EH; van der Helm-van Mil AH; Huizinga TW
    Rheumatology (Oxford); 2016 Feb; 55(2):357-66. PubMed ID: 26385370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs.
    Figueiredo CP; Bang H; Cobra JF; Englbrecht M; Hueber AJ; Haschka J; Manger B; Kleyer A; Reiser M; Finzel S; Tony HP; Kleinert S; Wendler J; Schuch F; Ronneberger M; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Lorenz HM; Nuesslein H; Alten R; Henes J; Krueger K; Rech J; Schett G
    Ann Rheum Dis; 2017 Feb; 76(2):399-407. PubMed ID: 27323772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of abatacept tapering therapy for sustained remission in patients with rheumatoid arthritis: Prospective single-center study.
    Yoshida S; Kotani T; Kimura Y; Matsumura Y; Yoshikawa A; Tokai N; Ozaki T; Nagai K; Takeuchi T; Makino S; Arawaka S
    Int J Rheum Dis; 2019 Jan; 22(1):81-89. PubMed ID: 30168272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.